Ipamorelin 5 mg

Ipamorelin 5 mg contains a selective growth hormone secretagogue peptide. In research settings it is used to stimulate GH release via GHS-R1a receptor activation. In non-medical bodybuilding contexts, ipamorelin is commonly referenced for its GH-stimulating properties and favorable side effect profile, though such use falls outside approved indications.

Community protocols commonly reference ipamorelin being injected 1–3 times daily at doses of 200–300 mcg per injection, with bedtime administration strongly preferred to amplify the natural GH pulse during slow-wave sleep. Doses are typically timed on an empty stomach to maximize the GH response.

Ipamorelin does not suppress endogenous testosterone production because it acts on the GHS-R1a receptor rather than the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore generally not considered necessary after ipamorelin use alone. Community protocols typically reference 8–12 weeks on followed by a 4-week break.

Ipamorelin stimulates growth hormone release by selectively activating the GHS-R1a receptor in the pituitary and hypothalamus. Unlike earlier GHRPs, ipamorelin does not stimulate ACTH or cortisol secretion and is highly selective for GH. This selectivity profile distinguishes it from GHRP-2 and GHRP-6.

Ipamorelin has a terminal half-life of approximately 2 hours, meaning each injection produces a short, pulsatile GH release. Community reports typically describe sleep quality improvements within 1–2 weeks, with recovery and body composition changes emerging over 8–12 weeks of consistent use.

There is no single GH secretagogue that is universally best. Ipamorelin is the most selective, producing clean GH release with minimal cortisol, prolactin, and appetite effects. GHRP-2 produces stronger GH stimulation but with more side effects, while Hexarelin produces the strongest GH pulse but desensitizes rapidly. The appropriate choice depends on individual goals.

Ipamorelin is more selective than GHRP-2, producing clean GH release without significant cortisol or prolactin elevation. GHRP-2 produces stronger GH stimulation but with more pronounced side effects. Ipamorelin is also more tolerable, with minimal appetite stimulation compared to GHRP-2.

Ipamorelin is significantly more selective than GHRP-6, which produces pronounced appetite stimulation and moderate cortisol elevation. GHRP-6 is often referenced for bulking contexts where increased caloric intake is desired, while ipamorelin is preferred for its clean side effect profile and suitability for longer protocols.

200 mcg is a standard starting dose in community protocols, with 200–300 mcg per injection being the most commonly referenced range. The 5 mg vial contains 5,000 mcg total, providing 16–25 doses at these levels. Doses are typically administered 1–3 times daily depending on the protocol.

Ipamorelin 5 mg is labeled at 5 mg of ipamorelin per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

Yes. A published laboratory report dated November 20, 2023 measured Ipamorelin 5 mg at 5.60 mg, equivalent to 112% of its 5 mg label claim. The batch number for this report is #HDIPM923.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

Lyophilized ipamorelin is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution, directing the solvent against the vial wall rather than onto the powder.